Long time immunogenicity of measles vaccine in the vaccination era: An open question.
After WHO European Region determined the 2005 - 2010 Strategic Plan for measles elimination, the number of reported measles cases in Europe fell dramatically. This decrease is related to the vaccination strategy carried out by European countries. This extensive immunization strategy changes the epidemiological patter and could influence the effectiveness and the long-time immunogenicity of the vaccine. To evaluate the long-time immunogenicity of the measles vaccine in the vaccination era, a pilot study among vaccinated blood donors in Apulia was designed. Of 174 enrolled patients, 93.7% presented an anti-measles IgG titer positive. GMT seems to increase by age (p = 0.001). The GMT seems to increase by age and this could be related to the exposition to natural boosters, that was more probable before the beginning of universal mass vaccination against measles. Future studies have to focus the correlation between GMT and age.
a Department of Biomedical Science and Human Oncology , Aldo Moro University of Bari , Bari , Italy.
Maria Serena
MS
Gallone
a Department of Biomedical Science and Human Oncology , Aldo Moro University of Bari , Bari , Italy.
Cinzia
C
Germinario
b Hygiene Department , Policlinico General Hospital , Bari , Italy.
Angela
A
Larocca
a Department of Biomedical Science and Human Oncology , Aldo Moro University of Bari , Bari , Italy.
Silvio
S
Tafuri
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D001782:Blood Donors; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007558:Italy; D008297:Male; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000276:immunology*; D010865:Pilot Projects; D013997:Time Factors; D055815:Young Adult
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D008458:Measles Vaccine
anti-measles IgG; geometric mean titer; measles elimination; vaccination strategy
Eur J Pediatr. 2012 Mar;171(3):463-70
21935584
Int J Infect Dis. 2002 Sep;6(3):202-9
12718836
Euro Surveill. 2008 Apr 17;13(16):null
18768120
Curr Opin Immunol. 2015 Aug;35:48-54
26091979
Euro Surveill. 2007 Apr 05;12(4):E070405.1
17439799
Euro Surveill. 2014 May 15;19(19):null
24852957
Virol J. 2007 Sep 21;4:90
17888162
Vaccine. 2011 Jul 18;29(32):5130-6
21624412
J Infect Dis. 2011 Jul;204 Suppl 1:S325-34
21666181
Rev Esp Salud Publica. 2015 Jul-Aug;89(4):345-51
26580789
Infect Immun. 1999 Aug;67(8):4064-71
10417175